Drug intelligence / Profile preview

MDI-1228

Development stage: Phase 2
Lead developer: Zhuhai Rui-Inno Pharmaceutical Technology
Modality: Small Molecules
Administration: Topical, Ophthalmic

Overview

MDI-1228 is a small molecule drug under development for the treatment of atopic dermatitis (mild and moderate) and allergic conjunctivitis. It is administered topically as a gel or as an ophthalmic solution. The drug is being developed by Henan Maiyingnuo Pharmaceutical Technology and Shanghai Meiyinnuo Pharmaceutical Technology, with clinical trials currently in Phase 2 for atopic dermatitis and Phase 1 for allergic conjunctivitis. The precise mechanism of action has not been disclosed in public sources[1][2][4].

Brand names: MDI-1228MDI1228MDI 1228
Other names: MDI-1228_mesylateMDI-1228MDI1228MDI 1228

Targets

JAK (Janus kinase family)

Beyond the preview

Go deeper on MDI-1228.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDI-1228.

Explore the full profile